Tagged Articles

major 3 articles

Contamination risk remains with Pharma Tech liquid docusate

The Food and Drug Administration (FDA) is reminding health care professionals and patients not to use any liquid product manufactured by Pharma Tech LLC’s Davie, Florida, facility because they may be contaminated with Burkholderia cepacia, a bacteria that can cause serious, life-threatening infections in people with compromised immune systems and patients with chronic lung conditions such as cystic fibrosis. These Pharma Tech-produced products are labeled by a variety of companies including Rugby, Leader, Major, Centurion, and Mid Valley. Laboratory testing conducted by the FDA has identified B. cepacia in several bottles of Rugby Diocto (docusate sodium) oral liquid from lot ... Read More

Health care workers can resume use of stool softener after source of contamination found

Health care workers may resume use of the stool softener oral liquid docusate now that the source of bacterial contamination in some of the products has been confirmed by the Centers for Disease Control and Prevention (CDC) as being those manufactured by PharmaTech, the Food and Drug Administration (FDA) said. PharmaTech recalled more than 10 lots of the liquid stool softener in July after it was found to contain the bacteria Buckholderia cepacia, or B.cepacia. The bacteria was also found in the water system used to manufacture the product made by PharmaTech and distributed and labeled by six different companies – ... Read More

Experimental sleep aid helped test patients fall asleep faster, stay asleep longer

An experimental new drug to help insomniacs fall asleep faster and stay asleep longer is showing good results in clinical trials. Suvorexant, made by Merck, is a new type of sleep aid that works differently from others currently on the market. Suvorexant works by targeting and blocking chemical messengers known as orexins that are designed to keep you awake and alert. They originate in the hypothalamus, a major sleep center in the brain. The new drug was tested during a three-month period in two separate trials of more than 1,000 people who suffer from insomnia. Patients in the first trial ... Read More